Monthly roundup
October 2026 weight-loss news: retatrutide and EloraTZP trial results, CagriSema decision timing, a counterfeit Ozempic case, hidden sibutramine, Medicare open enrollment and dated prices.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- No new weight-loss medicine approval appeared in FDA press announcements from September 15 to October 5, 2026.[1]
- In TRIUMPH-2, investigational retatrutide lowered weight by up to 18.8% vs 5.1% with placebo in adults with type 2 diabetes.[8]
- The FDA announced charges in a counterfeit Ozempic case and warned consumers not to use LUZE Fit Intensity, which contains hidden sibutramine.[15]
- Medicare open enrollment runs October 15 to December 7; the GLP-1 Bridge $50 copay continues through 2027.[19]
In short: No new weight-loss medicine was approved between mid-September and October 5, 2026, but a lot happened around the edges. New trial results for three investigational treatments (retatrutide, CagriSema and a combination called EloraTZP) were presented at the European diabetes meeting (EASD); the FDA announced charges in a counterfeit Ozempic case and warned about a weight-loss product with a hidden drug; and Medicare open enrollment starts October 15. Here is what each item means, and what it does not.
We check every item against a primary source: the FDA, DailyMed, CMS, journals or ClinicalTrials.gov. Company press releases are labeled “company-reported”. Nothing here is advice for your own treatment; bring questions to your clinician. Earlier coverage lives in our research and news section.
This month in numbers
- -18.8%top-dose average weight change with investigational retatrutide in TRIUMPH-2 (adults with type 2 diabetes, 80 weeks)Bellido V et al., Lancet 2026
- 367adults in the Phase 2b EloraTZP trial reported on September 30 (company-reported)Eli Lilly
- Q4 2026when Novo Nordisk expects the FDA decision on CagriSemaNovo Nordisk
- $50Medicare GLP-1 Bridge copay, available through December 31, 2027CMS
Checked on October 6, 2026
Approvals and regulatory
LABEL CHANGE: Zepbound and Foundayo labels updated. The current Zepbound label on DailyMed (revised August 2026) was published on September 2, and the Foundayo label (published August 13) follows an FDA-approved Medication Guide update on August 4. Our medication pages are checked against these versions. Labels change for many reasons, from wording to new safety information, and our records note the version we read.
PENDING: CagriSema. Novo Nordisk filed CagriSema (cagrilintide plus semaglutide) with the FDA in December 2025 and said on September 30 that it still expects a decision in the fourth quarter of 2026. It is not approved; our CagriSema explainer covers the trials, including the head-to-head trial in which it did not match tirzepatide.
COMPOUNDING: FDA guidance updated October 1. The FDA refreshed its page on concerns with unapproved GLP-1 drugs. Its message is unchanged: compounded drugs are not FDA approved, and the semaglutide and tirzepatide shortages ended in 2025 and 2024. Its April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the list of bulk ingredients that outsourcing facilities may use was still a proposal when we checked. Background: compounded GLP-1s.
New studies
INVESTIGATIONAL: Retatrutide in type 2 diabetes (TRIUMPH-2). Published in The Lancet and presented at EASD, this trial gave 1,152 adults with type 2 diabetes and a BMI of 27 or more one of three doses of retatrutide, a weekly injection that acts on GIP, GLP-1 and glucagon receptors, or placebo. Average weight change, counting everyone randomized, was -11.9%, -16.8% and -18.8% by dose vs -5.1% with placebo. Lilly reported that HbA1c fell by up to 1.6 points. What it means: retatrutide’s results hold up in people with diabetes, who usually lose less weight. What it doesn’t: retatrutide is not approved; Lilly says it plans to submit it to the FDA in the first quarter of 2027.
| Item | Value |
|---|---|
| Placebo | 5.1% |
| Retatrutide low dose | 11.9% |
| Retatrutide middle dose | 16.8% |
| Retatrutide high dose | 18.8% |
Percent of body weight lost; treatment-regimen estimand. Investigational drug, not FDA approved.
Source: Bellido V et al., Lancet 2026 (TRIUMPH-2) (checked on October 6, 2026)
INVESTIGATIONAL: EloraTZP, an amylin plus tirzepatide combination (company-reported). Lilly reported a 48-week Phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes. The highest combination (eloralintide 9 mg with tirzepatide 15 mg) averaged -23.3% vs -14.8% with tirzepatide 15 mg alone and -3.0% with placebo, under an estimate that assumes everyone stayed on treatment. Stopping because of side effects ranged from 10.8% to 27.0% across combination arms vs 2.9% with tirzepatide alone. What it means: adding an amylin drug to tirzepatide added weight loss in this study. What it doesn’t: it is a mid-stage trial; Lilly plans Phase 3 by the end of 2026.
INVESTIGATIONAL: CagriSema data at EASD (company-reported). Novo Nordisk presented a 52-week brain-imaging study linking CagriSema to changed responses to high-calorie food cues, plus body-fat, organ-fat and bone findings from its REIMAGINE diabetes trials. Full papers were not yet published.
STUDY: Foundayo in type 2 diabetes (company-reported). Lilly said ACHIEVE-4 showed Foundayo was non-inferior to insulin glargine, with a 16% lower risk of a combined measure of heart and stroke events (MACE-4). Foundayo is approved for weight management; type 2 diabetes is still an investigational use. See orforglipron for the molecule.
How to read this month’s trial numbers
Three things make conference headlines look more alike than they are. First, the estimand: TRIUMPH-2 counts everyone who was randomized (a “treatment-regimen” estimate), while the EloraTZP numbers assume everyone stayed on treatment (an “efficacy” estimate), which gives larger figures. Second, the population: all three September studies we covered were in people with type 2 diabetes, who usually lose less weight on these medicines than people without diabetes. Third, the stage: TRIUMPH-2 is a Phase 3 trial published in a peer-reviewed journal, while EloraTZP is a mid-stage Phase 2b study announced by the company. None of these numbers can be compared directly with each other or with an approved medicine’s label.
For scale only: in their own placebo-controlled trials in people without diabetes, Wegovy averaged -14.9% at 68 weeks (STEP 1) and Zepbound 15 mg -20.9% at 72 weeks (SURMOUNT-1). Our Wegovy vs Zepbound page explains the one head-to-head trial between approved medicines.
Where the approved options stand
| Group | Approved for weight (October 6, 2026) | What changed this month |
|---|---|---|
| Weekly GLP-1 and GIP/GLP-1 injections | Wegovy, Wegovy HD, Zepbound | Zepbound label version updated on DailyMed (September 2) |
| Daily GLP-1 pills | Wegovy tablets, Foundayo | Foundayo diabetes data reported; diabetes use still investigational |
| Daily injections | Saxenda and generic liraglutide; Imcivree (rare conditions) | No change found |
| Other pills | Qsymia, Contrave, orlistat (Xenical, Alli), short-term phentermine | No change found |
| Under FDA review | None approved: CagriSema pending | Decision still expected in Q4 2026 (company) |
Safety alerts
SAFETY ALERT: Counterfeit Ozempic case. On September 29, the FDA announced that its investigation led to charges against two Indian nationals accused of distributing counterfeit Ozempic obtained from unauthorized sources in China between July 2023 and April 2024, with fake packaging, inserts, pen labels and needles. The FDA has issued public alerts about counterfeit Ozempic since December 2023.
SAFETY ALERT: Hidden sibutramine in a weight-loss product. On September 15, the FDA warned consumers not to buy or use LUZE Fit Intensity, promoted for weight loss online and possibly in stores, because it contains sibutramine, a drug not listed on the label. The FDA says sibutramine can significantly raise blood pressure or heart rate, a serious risk for people with heart disease, heart failure, irregular heartbeat or stroke. Sibutramine was withdrawn from the U.S. market in 2010. Our supplements guide explains why products sold as supplements are not FDA approved.
Prices and coverage
PRICE/COVERAGE: Medicare open enrollment, October 15 to December 7. This is when people with Medicare can change plans for 2027. Separately, the CMS Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers Wegovy (injection and tablets), Zepbound KwikPen and Foundayo for weight management for a $50 copay to people who meet its criteria. Our insurance guide explains the criteria in plain words.
PRICE/COVERAGE: Self-pay prices as of October 6. NovoCare Pharmacy lists Wegovy pens at $349 a month ($199 for the first two fills of the lowest doses for new patients through December 31), Wegovy HD at $399 and Wegovy tablets at $149 to $299. Lilly lists Zepbound KwikPen at $299 to $449 and Foundayo at $149 to $349, by dose. Novo has also announced that Wegovy’s list price will drop to $675 a month from January 1, 2027. Details: cost hub and Wegovy cost.
| Item | Low | High |
|---|---|---|
| Foundayo | $149 | $349 |
| Wegovy pens | $199 | $349 |
| Wegovy HD | $399 | $399 |
| Wegovy tablets | $149 | $299 |
| Zepbound KwikPen | $299 | $449 |
Ranges are by strength. Prescription required; offers often exclude government insurance. Prices change; confirm before you plan.
Source: NovoCare Pharmacy; Lilly Zepbound and Foundayo savings pages (checked on October 6, 2026)
Industry and pipeline
INDUSTRY: Novo licenses a once-weekly oral candidate. On September 29, Novo Nordisk announced an exclusive license to HRS-1596, a GLP-1/GIP dual receptor agonist from Hengrui Pharma designed as a once-weekly pill, for up to $2.6 billion including $300 million upfront. It is ready for Phase 1 trials, so any approval would be years away. Weekly pills would differ from today’s daily options; our oral GLP-1 guide explains the approved ones.
What we updated on InstaTuck
- New: every FDA-approved weight-loss medication compared, with statuses checked on DailyMed on October 6.
- New: 40 ways to lose weight compared by evidence, cost and effort.
- New: telehealth weight-loss programs compared, not ranked, with dated prices.
- New: questions to ask before starting a GLP-1, with a printable checklist.
- Checked: medication pages against the current labels, including Wegovy and Zepbound.
What’s coming next
| When | What to watch | Status |
|---|---|---|
| October 15 to December 7 | Medicare open enrollment for 2027 plans | Scheduled (Medicare.gov) |
| November 14 to 17 | ObesityWeek 2026, National Harbor, Maryland: new trial results often appear here | Scheduled |
| November 2026 | TRIUMPH-5, retatrutide vs tirzepatide head-to-head: primary completion listed for this month | Results timing set by Lilly |
| Q4 2026 | FDA decision on CagriSema expected | Company expectation |
| Q1 2027 | Lilly’s planned FDA submission for retatrutide | Company plan |
| January 1, 2027 | Wegovy list price set to drop to $675 a month | Company announcement |
Looking for the bigger picture? Our what’s new in weight loss in 2026 piece sorts this year’s changes into proven, promising and hype, and the emerging medications page tracks every investigational candidate. For the approved options and how they work, start at the medications hub or the GLP-1 guide.
Records in this article
FDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · Weekly
FDA approved for weight managementPrescriptionPillWegovy Pill (oral semaglutide): status, how it is taken, how it comparesSemaglutide: one ingredient, several brands · Pill (tablet) · Daily
FDA approved for weight managementPrescriptionPillOrlistat (Xenical and Alli): how the fat-blocker worksCapsule · DailyRelated guides
Online Dietitian Services Compared: Insurance, Cost and What’s IncludedFive online dietitian services compared, alphabetical and not ranked: insurance, self-pay prices, visit length, messaging, states…
GLP-1 Medication vs a Diet Program: Results, Costs and Trade-offsGLP-1 medication vs a diet program compared: average weight loss in STEP, SURMOUNT, Look AHEAD and…
Ozempic vs Mounjaro: How the Two Diabetes Drugs DifferOzempic vs Mounjaro compared from the FDA labels and the SURPASS-2 head-to-head trial: approved uses, how…
Does Insurance Cover GLP-1s for Weight Loss? (checked quarterly)Does insurance cover GLP-1s for weight loss? Employer data, Medicare rules and the $50 GLP-1 Bridge,…Questions to ask a professional
- Does any news this month change anything about my current treatment?
- Would I be eligible for a clinical trial of a new medicine?
- Does my Medicare or other plan cover the weight medicine we are considering for 2027?
- How can I make sure my medicine comes from a legitimate pharmacy?
Frequently asked questions
Was a new weight-loss drug approved in September 2026?
No new weight-loss medicine approval appeared in FDA press announcements from September 15 to October 5, 2026. CagriSema is under FDA review, with a decision expected by Novo Nordisk in the fourth quarter of 2026.
Is retatrutide available?
No. Retatrutide is investigational and available only in clinical trials. Lilly says it plans to submit it to the FDA in the first quarter of 2027.
What is EloraTZP?
An investigational combination of eloralintide, an amylin receptor agonist, with tirzepatide. In a 48-week Phase 2b trial in adults with type 2 diabetes, Lilly reported up to 23.3% average weight loss vs 14.8% with tirzepatide alone. Phase 3 is planned.
How can I tell if my Ozempic or Wegovy is real?
Fill prescriptions at a state-licensed pharmacy, check packaging and pen labels, and contact the pharmacist or maker if anything looks off. The FDA has issued alerts about counterfeit Ozempic since December 2023.
When can I change my Medicare plan?
Medicare open enrollment runs from October 15 to December 7 each year. Plans differ in what they cover, so compare drug coverage carefully.
References
- FDA press announcements (September 15 to October 5, 2026 listing). U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- FOUNDAYO (orforglipron) tablets: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Drugs@FDA: Foundayo, NDA 220934. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- Novo’s investigational obesity and diabetes drug CagriSema reduces “food noise” and shows benefits in organ and bone health (EASD 2026). Novo Nordisk A/S, 2026. (accessed October 7, 2026) News (reported facts only)
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
- FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B bulks list. U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
- Bellido V, le Roux CW, Ekinci EI, et al.. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). The Lancet, 2026. doi:10.1016/S0140-6736(26)01861-1 · PMID 42810372 · NCT05929079 (accessed October 7, 2026) Randomized trial
- Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction (BLA planned Q1 2027). Eli Lilly and Company (press release), 2026. (accessed October 7, 2026) News (reported facts only)
- Lilly EloraTZP Phase 2b results (company announcement). Eli Lilly and Company, 2026. (accessed October 6, 2026) News (reported facts only)
- Lilly to present new data on Foundayo, retatrutide and EloraTZP at EASD 2026 (ACHIEVE-4). Eli Lilly and Company, 2026. (accessed October 6, 2026) News (reported facts only)
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi:10.1056/NEJMoa2206038 · PMID 35658024 · NCT04184622 (accessed October 7, 2026) Randomized trial
- FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme. U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
- FDA notification: weight-loss product may be harmful due to hidden ingredient (sibutramine). U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
- Questions and answers about FDA’s initiative against contaminated weight loss products. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
- BeSafeRx: your source for online pharmacy information. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
- Joining a plan (Open Enrollment: October 15 to December 7). Medicare.gov (CMS). (accessed October 7, 2026) Government page
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus. Novo Nordisk (press release), 2026. (accessed October 7, 2026) News (reported facts only)
- Novo Nordisk and Hengrui Pharma license agreement for HRS-1596. Novo Nordisk A/S, 2026. (accessed October 6, 2026) News (reported facts only)
- ObesityWeek 2026 (November 14-17, National Harbor, MD). The Obesity Society and ASMBS. (accessed October 6, 2026) Society statement
- TRIUMPH-5: retatrutide compared with tirzepatide in adults with obesity (NCT06662383). ClinicalTrials.gov (NLM). NCT06662383 (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.
Leave a Reply